BioXcel Therapeutics (BTAI) Amortization of Deferred Charges (2022 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Amortization of Deferred Charges of $502000.0 for Q1 2026, up 535.44% year-over-year from $79000.0 in Q1 2025, and up 7.04% quarter-over-quarter from $469000.0 in Q4 2025.
BioXcel Therapeutics (BTAI) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $502000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 535.44% year-over-year to $502000.0; the TTM figure through Mar 2026 stood at $1.8 million (up 258.85% YoY), while the FY2025 annual figure was $1.7 million, up 253.75% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $502000.0, up from $469000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $502000.0 in Q1 2026, with the low at -$267000.0 in Q4 2022.
- The 5-year median for Amortization of Deferred Charges is $264500.0 (2023), against an average of $233250.0.
- The sharpest annual moves came in 2024 and 2026: Amortization of Deferred Charges slumped 73.03% in 2024, then soared 535.44% in 2026.
- BioXcel Therapeutics' Amortization of Deferred Charges stood at -$267000.0 in 2022, then soared by 214.98% to $307000.0 in 2023, then dropped by 27.69% to $222000.0 in 2024, then surged by 111.26% to $469000.0 in 2025, then climbed by 7.04% to $502000.0 in 2026.
- Business Quant data shows BTAI's Amortization of Deferred Charges at $502000.0 in Q1 2026, $469000.0 in Q4 2025, and $441000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | BioXcel Therapeutics | 24.36 Mn | 24.36 Mn | 160,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 774,000.00 |
| Jun 30, 2026 | 774,000.00 |
| Mar 31, 2026 | 502,000.00 |
| Mar 31, 2026 | 502,000.00 |
| Dec 31, 2025 | 469,000.00 |
| Dec 31, 2025 | 469,000.00 |
| Sep 30, 2025 | 441,000.00 |
| Sep 30, 2025 | 441,000.00 |
| Jun 30, 2025 | 393,000.00 |
| Jun 30, 2025 | 393,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Dec 31, 2024 | 222,000.00 |
| Dec 31, 2024 | 222,000.00 |
| Sep 30, 2024 | 106,000.00 |
| Sep 30, 2024 | 106,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 43,000.00 |
| Mar 31, 2024 | 43,000.00 |